Janney Montgomery Scott LLC Increases Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

Janney Montgomery Scott LLC raised its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 42.0% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 52,592 shares of the company's stock after acquiring an additional 15,545 shares during the quarter. Janney Montgomery Scott LLC owned approximately 0.18% of Krystal Biotech worth $8,239,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of KRYS. Crossmark Global Holdings Inc. increased its holdings in Krystal Biotech by 5.5% in the fourth quarter. Crossmark Global Holdings Inc. now owns 2,307 shares of the company's stock valued at $362,000 after purchasing an additional 121 shares during the period. KBC Group NV raised its position in shares of Krystal Biotech by 25.9% during the third quarter. KBC Group NV now owns 642 shares of the company's stock worth $117,000 after acquiring an additional 132 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Krystal Biotech by 3.4% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,614 shares of the company's stock worth $840,000 after acquiring an additional 153 shares during the period. Pier 88 Investment Partners LLC boosted its holdings in Krystal Biotech by 5.1% in the third quarter. Pier 88 Investment Partners LLC now owns 3,530 shares of the company's stock valued at $643,000 after acquiring an additional 170 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in Krystal Biotech by 21.8% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,039 shares of the company's stock valued at $184,000 after purchasing an additional 186 shares during the period. Institutional investors own 86.29% of the company's stock.

Insider Activity

In related news, insider Suma Krishnan sold 25,000 shares of the firm's stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $164.78, for a total value of $4,119,500.00. Following the transaction, the insider now owns 1,475,882 shares of the company's stock, valued at approximately $243,195,835.96. This trade represents a 1.67 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 14.10% of the company's stock.

Krystal Biotech Stock Up 2.4 %

NASDAQ:KRYS traded up $3.67 during trading hours on Friday, reaching $159.74. The company had a trading volume of 206,811 shares, compared to its average volume of 247,021. The business's 50-day simple moving average is $166.27 and its two-hundred day simple moving average is $180.01. Krystal Biotech, Inc. has a twelve month low of $107.50 and a twelve month high of $219.34. The firm has a market cap of $4.59 billion, a price-to-earnings ratio of 90.25 and a beta of 0.85.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its earnings results on Monday, November 4th. The company reported $0.91 EPS for the quarter, beating analysts' consensus estimates of $0.84 by $0.07. The business had revenue of $83.84 million during the quarter, compared to analyst estimates of $82.94 million. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The firm's revenue was up 879.9% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.67) EPS. As a group, equities analysts predict that Krystal Biotech, Inc. will post 3.03 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have recently commented on KRYS. Citigroup upped their price objective on shares of Krystal Biotech from $204.00 to $206.00 and gave the company a "neutral" rating in a research note on Tuesday, November 5th. Chardan Capital reaffirmed a "buy" rating and set a $212.00 price target on shares of Krystal Biotech in a research report on Wednesday, December 18th. Finally, HC Wainwright reissued a "buy" rating and issued a $221.00 price objective on shares of Krystal Biotech in a research report on Wednesday, December 18th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $206.67.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).